Understanding and managing secondary osteoporosis

References

• Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520–2526.
   PubMed Web of Science ®Google Scholar
• Minisola S, Cipriani C, Occhiuto M, et al. New anabolic therapies for osteoporosis. Intern Emerg Med. 2017;12(7):915–921.
   PubMed Web of Science ®Google Scholar
• Adami S, Isaia G, Luisetto G, et al. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res. 2006;21(10):1565–1570.
   PubMed Web of Science ®Google Scholar
• Diez-Perez A, Adachi JD, Agnusdei D, et al. Treatment failure in osteoporosis. Osteoporos Int. 2012;23(12):2769–2774.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002;77(5):453–468.
   PubMed Web of Science ®Google Scholar
• Romagnoli E, Del Fiacco R, Russo S, et al. Secondary osteoporosis in men and women: clinical challenge of an unresolved issue. J Rheumatol. 2011;38(8):1671–1679.
   PubMed Web of Science ®Google Scholar
• Williams GR, Bassett JHD. Thyroid diseases and bone health. J Endocrinol Invest. 2018;41(1):99–109.
   PubMed Web of Science ®Google Scholar
• Blum MR, Bauer DC, Collet TH, et al. Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015;313(20):2055–2065.
   PubMed Web of Science ®Google Scholar
• Segna D, Bauer DC, Feller M, et al. Association between subclinical thyroid dysfunction and change in bone mineral density in prospective cohorts. J Intern Med. 2018;283(1):56–72.
   PubMed Web of Science ®Google Scholar
• Rochira V, Antonio L, Vanderschueren D. EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology. 2018;6(2):272–285.
   PubMed Web of Science ®Google Scholar
• Minisola S, Pepe J, Scillitani A, et al. Explaining geographical variation in the presentation of primary hyperparathyroidism. Lancet Diabetes Endocrinol. 2016;4(8):641–643.
   PubMed Web of Science ®Google Scholar
• Cipriani C, Biamonte F, Costa AG, et al. Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. J Clin Endocrinol Metab. 2015;100(4):1309–1315.
   PubMed Web of Science ®Google Scholar
• Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab. 2014;99(10):3561–3569.
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu X, Li H. Long-term skeletal outcomes of primary hyperparathyroidism patients after treatment with parathyroidectomy: a systematic review and meta-analysis. Horm Metab Res. 2018;50(3):242–249.
   PubMed Web of Science ®Google Scholar
• Eller-Vainicher C, Palmieri S, Cairoli E, et al. Protective effect of denosumab on bone in older women with primary hyperparathyroidism. J Am Geriatr Soc. 2018;66(3):518–524.
   PubMed Web of Science ®Google Scholar
• Cesareo R, Di Stasio E, Vescini F, et al. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int. 2015;26(4):1295–1302.
   PubMed Web of Science ®Google Scholar
• Napoli N, Chandran M, Pierroz DD, et al. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13(4):208–219.
   PubMed Web of Science ®Google Scholar
• Ferrari SL, Abrahamsen B, Napoli N, et al. Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos Int. 2018;29(12):2585–2596.
   Web of Science ®Google Scholar
• Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011;305(21):2184–2192.
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Paschou SA, Gkekas NN, et al. Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review. Endocrine. 2018;60(3):373–383.
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Frara S, Giustina A. Pituitary diseases and bone. Endocr Rev. 2018;39(4):440–488.
   PubMed Web of Science ®Google Scholar
• Tritos NA. Focus on growth hormone deficiency and bone in adults. Best Pract Res Clin Endocrinol Metab. 2017;31(1):49–57.
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Biagioli E, Maffezzoni F, et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2015;100(2):384–394.
   PubMed Web of Science ®Google Scholar
• Chiodini I, Torlontano M, Carnevale V, et al. Skeletal involvement in adult patients with endogenous hypercortisolism. J Endocrinol Invest. 2008;31(3):267–276.
   PubMed Web of Science ®Google Scholar
• Salcuni AS, Carnevale V, Battista C, et al. Primary aldosteronism as a cause of secondary osteoporosis. Eur J Endocrinol. 2017;177(5):431–437.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Lee SH, Koh JM. Bone health in adrenal disorders. Endocrinol Metab (Seoul). 2018;33(1):1–8.
   PubMedGoogle Scholar
• Balk EM, Adam GP, Langberg VN, et al. Global dietary calcium intake among adults: a systematic review. Osteoporos Int. 2017;28(12):3315–3324.
   PubMed Web of Science ®Google Scholar
• Minisola S, Pepe J, Donato P, et al. Replenishment of vitamin D status: theoretical and practical considerations. Hormones (Athens). 2018.
   PubMedGoogle Scholar
• Drabkin A, Rothman MS, Wassenaar E, et al. Assessment and clinical management of bone disease in adults with eating disorders: a review. J Eat Disord. 2017;5:42.
   PubMed Web of Science ®Google Scholar
• Robinson L, Aldridge V, Clark EM, et al. Pharmacological treatment options for low Bone Mineral Density and secondary osteoporosis in anorexia nervosa: a systematic review of the literature. J Psychosom Res. 2017;98:87–97.
   PubMed Web of Science ®Google Scholar
• Napartivaumnuay N, Gramlich L. The prevalence of Vitamin D insufficiency and deficiency and their relationship with bone mineral density and fracture risk in adults receiving long-term home parenteral nutrition. Nutrients. 2017;9(5).
   PubMed Web of Science ®Google Scholar
• Cipriani C, Pepe J, Piemonte S, et al. Vitamin D and its relationship with obesity and muscle. Int J Endocrinol. 2014;2014:841248.
   PubMed Web of Science ®Google Scholar
• Pepe J, Cipriani C, Cilli M, et al. Adipokines and bone metabolism: an interplay to untangle. J Endocrinol Invest. 2016;39(11):1359–1361.
   PubMed Web of Science ®Google Scholar
• Li X, Gong X, Jiang W. Abdominal obesity and risk of hip fracture: a meta-analysis of prospective studies. Osteoporos Int. 2017;28(10):2747–2757.
   PubMed Web of Science ®Google Scholar
• Savvidis C, Tournis S, Dede AD. Obesity and bone metabolism. Hormones (Athens). 2018;17(2):205–217.
   PubMedGoogle Scholar
• Gagnon C, Schafer AL. Bone health after bariatric surgery. JBMR Plus. 2018;2(3):121–133.
   PubMedGoogle Scholar
• Xue AL, Wu SY, Jiang L, et al. Bone fracture risk in patients with rheumatoid arthritis: a meta-analysis. Medicine (Baltimore). 2017;96(36):e6983.
   PubMed Web of Science ®Google Scholar
• Hoes JN, Bultink IE, Lems WF. Management of osteoporosis in rheumatoid arthritis patients. Expert Opin Pharmacother. 2015;16(4):559–571.
   PubMed Web of Science ®Google Scholar
• Dubrovsky AM, Lim MJ, Lane NE. Osteoporosis in rheumatic diseases: anti-rheumatic drugs and the skeleton. Calcif Tissue Int. 2018;102(5):607–618.
   PubMed Web of Science ®Google Scholar
• Boleto G, Drame M, Lambrecht I, et al. Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature. Clin Rheumatol. 2017;36(8):1699–1706.
   PubMed Web of Science ®Google Scholar
• Ebina K, Hirao M, Hashimoto J, et al. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis. J Bone Miner Metab. 2018;36(4):478–487.
   PubMed Web of Science ®Google Scholar
• Kinoshita H, Miyakoshi N, Kashiwagura T, et al. Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis. Mod Rheumatol. 2017;27(4):582–586.
   PubMed Web of Science ®Google Scholar
• Walsh JA, Song X, Kim G, et al. Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set. Clin Rheumatol. 2018;37(7):1869–1878.
   PubMed Web of Science ®Google Scholar
• Zhang M, Li XM, Wang GS, et al. The association between ankylosing spondylitis and the risk of any, hip, or vertebral fracture: a meta-analysis. Medicine (Baltimore). 2017;96(50):e8458.
   PubMed Web of Science ®Google Scholar
• Magrey MN, Khan MA. The paradox of bone formation and bone loss in ankylosing spondylitis: evolving new concepts of bone formation and future trends in management. Curr Rheumatol Rep. 2017;19(4):17.
   PubMed Web of Science ®Google Scholar
• Carli L, Tani C, Spera V, et al. Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus. Lupus Sci Med. 2016;3(1):e000098.
   PubMed Web of Science ®Google Scholar
• Hassanalilou T, Khalili L, Ghavamzadeh S, et al. Role of vitamin D deficiency in systemic lupus erythematosus incidence and aggravation. Auto Immun Highlights. 2017;9(1):1.
   PubMed Web of Science ®Google Scholar
• Mak A. The impact of vitamin D on the immunopathophysiology, disease activity, and extra-musculoskeletal manifestations of systemic lupus erythematosus. Int J Mol Sci. 2018;19(8).
   Web of Science ®Google Scholar
• Rossini M, Viapiana O, Adami S, et al. In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clin Exp Rheumatol. 2015;33(1):77–83.
   PubMed Web of Science ®Google Scholar
• Mirza F, Canalis E. Management of endocrine disease: secondary osteoporosis: pathophysiology and management. Eur J Endocrinol. 2015;173(3):R131–R151.
   PubMed Web of Science ®Google Scholar
• Danford CJ, Trivedi HD, Papamichael K, et al. Osteoporosis in primary biliary cholangitis. World J Gastroenterol. 2018;24(31):3513–3520.
   PubMed Web of Science ®Google Scholar
• Guanabens N, Ruiz-Gaspa S, Gifre L, et al. Sclerostin expression in bile ducts of patients with chronic cholestasis may influence the bone disease in primary biliary cirrhosis. J Bone Miner Res. 2016;31(9):1725–1733.
   PubMed Web of Science ®Google Scholar
• Santos LA, Romeiro FG. Diagnosis and management of cirrhosis-related osteoporosis. Biomed Res Int. 2016;2016:1423462.
   PubMedGoogle Scholar
• Nitta K, Yajima A, Tsuchiya K. Management of osteoporosis in chronic kidney disease. Intern Med. 2017;56(24):3271–3276.
   PubMed Web of Science ®Google Scholar
• Graciolli FG, Neves KR, Barreto F, et al. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. Kidney Int. 2017;91(6):1436–1446.
   PubMed Web of Science ®Google Scholar
• Pimentel A, Urena-Torres P, Zillikens MC, et al. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. Kidney Int. 2017;92(6):1343–1355.
   PubMed Web of Science ®Google Scholar
• Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis. 2016;67(4):559–566.
   PubMed Web of Science ®Google Scholar
• Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36.
   PubMed Web of Science ®Google Scholar
• Giannini S, Mazzaferro S, Minisola S, et al. Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion. Endocrine. 2018;59(2):242–259.
   PubMed Web of Science ®Google Scholar
• Massy Z, Drueke T. Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease. J Nephrol. 2017;30(5):629–634.
   PubMed Web of Science ®Google Scholar
• Winocour PH. Diabetes and chronic kidney disease: an increasingly common multi-morbid disease in need of a paradigm shift in care. Diabet Med. 2018;35(3):300–305.
   PubMed Web of Science ®Google Scholar
• Nuti R, Brandi ML, Checchia G, et al. Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med. 2019;14(1):85–102.
   PubMed Web of Science ®Google Scholar
• Coe FL, Worcester EM, Evan AP. Idiopathic hypercalciuria and formation of calcium renal stones. Nat Rev Nephrol. 2016;12(9):519–533.
   PubMed Web of Science ®Google Scholar
• Ryan LE, Ing SW. Idiopathic hypercalciuria: can we prevent stones and protect bones?. Cleve Clin J Med. 2018;85(1):47–54.
   PubMed Web of Science ®Google Scholar
• Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018;61(1):7–16.
   PubMed Web of Science ®Google Scholar
• Maricic M, Deal C, Dore R, et al. 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis: comment on the article by Buckley et al. Arthritis Care Res (Hoboken). 2018;70(6):949–950.
   PubMed Web of Science ®Google Scholar
• Shaiykova A, Pasquet A, Goujard C, et al. Reduced bone mineral density among HIV-infected, virologically controlled young men: prevalence and associated factors. AIDS. 2018;32(18):2689–2696.
   PubMedGoogle Scholar
• Rachner TD, Coleman R, Hadji P, et al. Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol. 2018;6(11):901–910.
   Web of Science ®Google Scholar
• Nguyen KD, Bagheri B, Bagheri H. Drug-induced bone loss: a major safety concern in Europe. Expert Opin Drug Saf. 2018;17(10):1005–1014.
   PubMed Web of Science ®Google Scholar
• Andersen BN, Johansen PB, Abrahamsen B. Proton pump inhibitors and osteoporosis. Curr Opin Rheumatol. 2016;28(4):420–425.
   PubMed Web of Science ®Google Scholar
• Ilha T, Comim FV, Copes RM, et al. HIV and vertebral fractures: a systematic review and metanalysis. Sci Rep. 2018;8(1):7838.
   PubMedGoogle Scholar
• Borderi M, Calza L, Colangeli V, et al. Prevalence of sub-clinical vertebral fractures in HIV-infected patients. New Microbiol. 2014;37(1):25–32.
   PubMed Web of Science ®Google Scholar
• Torti C, Mazziotti G, Soldini PA, et al. High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine. 2012;41(3):512–517.
   PubMed Web of Science ®Google Scholar
• Pepe J, Isidori AM, Falciano M, et al. The combination of FRAX and Ageing Male Symptoms scale better identifies treated HIV males at risk for major fracture. Clin Endocrinol (Oxf). 2012;77(5):672–678.
   PubMed Web of Science ®Google Scholar
• Noe S, Oldenbuettel C, Heldwein S, et al. Secondary hyperparathyroidism in HIV-infected patients in Central Europe. Horm Metab Res. 2018;50(4):317–324.
   PubMed Web of Science ®Google Scholar
• Saint-Pastou Terrier C, Gasque P. Bone responses in health and infectious diseases: a focus on osteoblasts. J Infect. 2017;75(4):281–292.
   PubMed Web of Science ®Google Scholar
• Mirza FS, Luthra P, Chirch L. Endocrinological aspects of HIV infection. J Endocrinol Invest. 2018;41(8):881–899.
   PubMed Web of Science ®Google Scholar
• Huang JS, Rietschel P, Hadigan CM, et al. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS. 2001;15(8):975–982.
   PubMed Web of Science ®Google Scholar
• Rendina-Ruedy E, Rosen CJ. Bone-fat interaction. Endocrinol Metab Clin North Am. 2017;46(1):41–50.
   PubMed Web of Science ®Google Scholar
• Brown TT, Hoy J, Borderi M, et al. Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis. 2015;60(8):1242–1251.
   PubMed Web of Science ®Google Scholar
• Veronese N, Luchini C, Solmi M, et al. Monoclonal gammopathy of undetermined significance and bone health outcomes: a systematic review and exploratory meta-analysis. J Bone Miner Metab. 2018;36(1):128–132.
   PubMed Web of Science ®Google Scholar
• Pepe J, Petrucci MT, Nofroni I, et al. Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134(5):485–490.
   PubMed Web of Science ®Google Scholar
• Bouvard B, Royer M, Chappard D, et al. Monoclonal gammopathy of undetermined significance, multiple myeloma, and osteoporosis. Joint Bone Spine. 2010;77(2):120–124.
   PubMed Web of Science ®Google Scholar
• Drake MT. unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance? J Bone Miner Res. 2014;29(12):2529–2533.
   PubMed Web of Science ®Google Scholar
• Pepe J, Petrucci MT, Mascia ML, et al. The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance. Calcif Tissue Int. 2008;82(6):418–426.
   PubMed Web of Science ®Google Scholar
• Berenson JR, Yellin O, Boccia RV, et al. Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss. Clin Cancer Res. 2008;14(19):6289–6295.
   PubMed Web of Science ®Google Scholar
• Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370–381.
   PubMed Web of Science ®Google Scholar
• Degboe Y, Eischen M, Nigon D, et al. Prevalence and risk factors for fragility fracture in systemic mastocytosis. Bone. 2017;105:219–225.
   PubMed Web of Science ®Google Scholar
• Rossini M, Zanotti R, Orsolini G, et al. Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporos Int. 2016;27(8):2411–2421.
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Soliman AT, Elsefdy H, et al. Bone disease in beta thalassemia patients: past, present and future perspectives. Metabolism. 2018;80:66–79.
   PubMed Web of Science ®Google Scholar
• Chen YG, Lu CS, Lin TY, et al. Risk of fracture in transfusion-naive thalassemia population: a nationwide population-based retrospective cohort study. Bone. 2018;106:121–125.
   PubMed Web of Science ®Google Scholar
• Poggi M, Sorrentino F, Pugliese P, et al. Longitudinal changes of endocrine and bone disease in adults with beta-thalassemia major receiving different iron chelators over 5 years. Ann Hematol. 2016;95(5):757–763.
   PubMed Web of Science ®Google Scholar
• Laszkowska M, Mahadev S, Sundstrom J, et al. Systematic review with meta-analysis: the prevalence of coeliac disease in patients with osteoporosis. Aliment Pharmacol Ther. 2018;48(6):590–597.
   PubMed Web of Science ®Google Scholar
• Duerksen D, Pinto-Sanchez MI, Anca A, et al. Management of bone health in patients with celiac disease: practical guide for clinicians. Can Fam Physician. 2018;64(6):433–438.
   PubMed Web of Science ®Google Scholar
• Larussa T, Suraci E, Imeneo M, et al. Normal bone mineral density associates with duodenal mucosa healing in adult patients with celiac disease on a gluten-free diet. Nutrients. 2017;9:2.
   Web of Science ®Google Scholar
• Szafors P, Che H, Barnetche T, et al. Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. Osteoporos Int. 2018.
   PubMed Web of Science ®Google Scholar
• Komaki Y, Komaki F, Micic D, et al. Risk of fractures in inflammatory bowel diseases: a systematic review and meta-analysis. J Clin Gastroenterol. 2018. [Epub ahead of print].
   Web of Science ®Google Scholar
• Pepe J, Zawadynski S, Herrmann FR, et al. Structural basis of bone fragility in young subjects with inflammatory bowel disease: a high-resolution pQCT Study of the SWISS IBD Cohort (SIBDC). Inflamm Bowel Dis. 2017;23(8):1410–1417.
   PubMed Web of Science ®Google Scholar
• Krajcovicova A, Hlavaty T, Killinger Z, et al. Combination therapy with an immunomodulator and anti-TNFalpha agent improves bone mineral density in IBD patients. J Crohns Colitis. 2014;8(12):1693–1701.
   PubMed Web of Science ®Google Scholar
• Yao L, Wang H, Dong W, et al. Efficacy and safety of bisphosphonates in management of low bone density in inflammatory bowel disease: a meta-analysis. Medicine (Baltimore). 2017;96(3):e5861.
   PubMed Web of Science ®Google Scholar
• Guanabens N, Pares A. Osteoporosis in chronic liver disease. Liver Int. 2018;38(5):776–785.
   PubMed Web of Science ®Google Scholar
• Giampietro PF, Peterson MG, Schneider R, et al. Bone mineral density determinations by dual-energy x-ray absorptiometry in the management of patients with Marfan syndrome–some factors which affect the measurement. HSS J. 2007;3(1):89–92.
   PubMedGoogle Scholar
• Mazziotti G, Dordoni C, Doga M, et al. High prevalence of radiological vertebral fractures in adult patients with Ehlers-Danlos syndrome. Bone. 2016;84:88–92.
   PubMed Web of Science ®Google Scholar
• Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008;93(9):3462–3470.
   PubMed Web of Science ®Google Scholar
• Marcocci C, Bollerslev J, Khan AA, et al. Medical management of primary hyperparathyroidism: proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 2014;99(10):3607–3618.
   PubMed Web of Science ®Google Scholar
• Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2017;69(8):1095–1110.
   PubMed Web of Science ®Google Scholar